This is the latest episode of the free DDW narrated podcast, titled “Critical tools that support drug discovery and development”, which covers two articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “You think you need an ELN… but are you asking the… Read More
This is the latest episode of the free DDW narrated podcast, titled “Critical tools that support drug discovery and development”, which covers two articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “You think you need an ELN… but are you… Read More
A newly published study in Nature Communications unveils a powerful new method for analysing some of the most complex regions of the human genome. Led by researchers from PacBio, GeneDx, and a global consortium of genomics experts, the study utilises Paraphase, an informatics tool that, when paired with HiFi long-read… Read More
EnteroBiotix, a clinical-stage biopharmaceutical company developing best-in-class drugs for gut health, has announced positive initial results with EBX-102-02, the company’s next-generation full-spectrum microbiome product, from the TrIuMPH Phase IIa clinical trial in adults with irritable bowel syndrome with constipation (IBS-C). The multicentre, randomised, double-blind, placebo-controlled TrIuMPH (Treating IBS with an… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Clinical trials of all stages have dominated the DDW news section this week. All… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Clinical trials of all stages have dominated the DDW news section this week. All… Read More
Dr Jason Williams, Founder and Director of Interventional Oncology and Immunotherapy at The Williams Cancer Institute, discusses leveraging immunotherapy and cryoablation for a new era in cancer treatment. The paradigm of cancer treatment is shifting. For decades, chemotherapy and radiation have been the pillars of oncology, but their limitations are… Read More
SpliceBio has dosed the first patient in the Phase I/II ASTRA study of SB-007, a dual adeno-associated viral (AAV) vector, for the treatment of Stargardt disease. Stargardt disease is an inherited retinal disorder caused by mutations in the ABCA4 gene. It is the most common form of juvenile macular degeneration,… Read More
This is the latest episode of the free DDW narrated podcast, titled “The revolutionary impact of understanding genomics”, which covers two articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “Open science, genomics, and the quiet revolution in our approach to pharma” and “… Read More
This is the latest episode of the free DDW narrated podcast, titled “The revolutionary impact of understanding genomics”, which covers two articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “Open science, genomics, and the quiet revolution in our approach to pharma”… Read More
Elsevier has launched ScienceDirect AI, a generative AI tool for researchers. It is designed to transform the way researchers work by enabling them to instantly extract, summarise and compare trusted insights from millions of full-text articles and book chapters on ScienceDirect, a platform for peer-reviewed research. Researchers engage with a… Read More
Pierre Fabre Laboratories and RedRidge have announced an exclusive R&D collaboration and license agreement to identify and develop biparatopic antibody (BPA) drug candidates against multiple targets. In line with Pierre Fabre Laboratories’ innovation strategy, the partnership’s therapeutic focus will be on precision oncology as well as dermatology and rare diseases. Read More
DDW’s Megan Thomas takes a wide-angle look at the sector and speaks to experts and thought leaders about their predictions for therapeutic antibodies in 2025. Clinical advancements Marcelo Freire, Vice President of Global Medical Affairs, Therapeutic Area Head of Gastroenterology at Takeda, comments on monoclonal antibodies (mAbs) from a gastro… Read More
Vivace Therapeutics has announced the closing of $35 million Series D financing to support the company’s small molecule cancer therapeutics targeting the Hippo pathway. The round was led by RA Capital Management, an existing investor, and included investment from other existing investors Canaan Partners and Cenova Capital. Proceeds will support… Read More
Bantam Pharmaceutical, a company targeting selective modulation of mitochondrial dynamics in cancer, is proceeding with a Phase I clinical trial evaluating BTM-3566 in relapsed/refractory (R/R) mature B-cell lymphomas, based on a recent Clinical Trial Application (CTA) cleared by Health Canada. This regulatory milestone enables Bantam to expand its ongoing clinical… Read More
OKYO Pharma, a clinical-stage biopharmaceutical company developing therapies for the treatment of neuropathic corneal pain and inflammatory dry eye disease has filed an application for Fast Track designation with the US Food and Drug Administration (FDA) for urcosimod (formerly known as OK-101). The company intends to use urcosimod for the… Read More
